Basic Information

Cell Line Name
Daudi Gt(AAVS1)tm1(luciferase)/Bcgen
Common Name
B-luc Daudi 
Catalog Number
Cell Type/Disease
Burkitt’s lymphoma
Culture Properties
RPMI1640+ 10% FBS+1% L-Glutamine+1% NEAA+1% Sodium pyruvate+1%HEPES
Digestive Solution
Cryopreservation Medium
95% Complete medium+5% DMSO

Targeting Strategy

Gene targeting strategy for B-luc Daudi. The luciferase cDNA sequence with CAG promoter was inserted in exon 1 of the AAVS1 locus of wild-type Daudi cells. 

Phenotypic Analysis

Luminescence signal intensity of B-luc Daudi cells. B-luc Daudi cells displayed strong luminescence signal intensity compared to wild-type Daudi cells, as detected by the Bright-GloTM luciferase Assay System (Promega, Cat E2610).

Tumor Growth Curve & Body Weight Changes

Subcutaneous xenograft tumor growth of B-luc Daudi cells. B-luc Daudi cells and wild-type Daudi cells (5×106) were subcutaneously implanted into B-NDG mice (n=5). (A) Average tumor volume ± SEM, and (B) body weight (Mean± SEM) were measured twice a week. Volume was expressed in mm3 using the formula: V=0.5a X b2, where a and b were the long and short diameters of the tumor, respectively. B-luc Daudi cells were able to establish tumors in vivo, which can be used for efficacy studies.

In Vivo Imaging Analysis

Tumor growth and in vivo imaging of B-luc Daudi cells. B-luc Daudi cells were injected by tail vein into B-NDG mice. (A) Imaging was performed on days 0, 3, 7, 10, 14, 17, 21, 24 and 28 for tumor detection and signal intensity analysis. (B) Body weight was measured twice a week (Mean ± SEM). Altogether these data indicate that B-luc Daudi cells can be used for in vivo efficacy evaluation.

Back to top